NASDAQ:ANIP

Ani Pharmaceuticals Stock Insider Trading

Healthcare > Drug Manufacturers - Specialty & Generic

Buy ANIP

*Your capital is at risk

$80.58

+1.09 (+1.37%)

At Close: Jun 22, 2026

ANI Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -79.24. In total, the insiders bought 220.09K and sold 338.44K ANIP shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-79.24
● Buy	220.09K shares
● Sell	338.44K shares
18% Buy Activity Negligible or No Correlation
Buy Signal Low Confidence Feb 26, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -79.24. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 07, 2026 Sell	Common Stock F-InKind	Mutz Christopher Head Of Rare Disease	Officer	3 314 Value: $245.4K
Mar 06, 2026 Sell	Common Stock S-Sale	Davis Krista SVP, Chief Hr Officer	Officer	1 485 Value: $111.4K
Mar 06, 2026 Sell	Common Stock S-Sale	Mutz Christopher Head Of Rare Disease	Officer	2 121 Value: $157.4K
Mar 05, 2026 Buy	Stock Option (right to buy) M-Exempt	Carey Stephen P. SVP & CFO	C-Suite Officer	3 312 Value: $164.0K
Mar 05, 2026 Sell	Common Stock S-Sale	Carey Stephen P. SVP & CFO	C-Suite Officer	4 000 Value: $302.2K
Mar 05, 2026 Sell	Common Stock S-Sale	Carey Stephen P. SVP & CFO	C-Suite Officer	3 312 Value: $249.8K
Mar 05, 2026 Buy	Common Stock M-Exempt	Carey Stephen P. SVP & CFO	C-Suite Officer	3 312 Value: $164.0K
Mar 03, 2026 Sell	Common Stock S-Sale	Gutwerg Ori SVP, Generics	Officer	2 060 Value: $157.6K
Mar 03, 2026 Sell	Common Stock S-Sale	Walsh Patrick D Director	Director	6 000 Value: $445.4K
Mar 02, 2026 Sell	Common Stock S-Sale	Mutz Christopher Head Of Rare Disease	Officer	417 Value: $30.9K
Feb 28, 2026 Sell	Common Stock F-InKind	Davis Krista SVP, Chief Hr Officer	Officer	1 555 Value: $114.9K
Feb 28, 2026 Sell	Common Stock F-InKind	Mutz Christopher Head Of Rare Disease	Officer	2 221 Value: $164.1K
Feb 28, 2026 Sell	Common Stock F-InKind	Rowland Thomas Andrew SVP, Head - Established Brands	Officer	628 Value: $46.4K
Feb 28, 2026 Sell	Common Stock F-InKind	Lalwani Nikhil President & CEO	CEO / President	12 217 Value: $902.8K
Feb 28, 2026 Sell	Common Stock F-InKind	Gutwerg Ori SVP, Generics	Officer	2 221 Value: $164.1K
Feb 28, 2026 Sell	Common Stock F-InKind	Gassert Chad SVP - Corp. Dev. & Strategy	Officer	2 221 Value: $164.1K
Feb 28, 2026 Sell	Common Stock F-InKind	Cook Meredith Sr. Vp, General Counsel & Sec.	Officer	1 555 Value: $114.9K
Feb 28, 2026 Sell	Common Stock F-InKind	Carey Stephen P. SVP & CFO	C-Suite Officer	2 773 Value: $204.9K
Feb 26, 2026 Buy	Common Stock A-Award	Davis Krista SVP, Chief Hr Officer	Officer	10 810 Value: $834.0K
Feb 26, 2026 Buy	Common Stock A-Award	Gassert Chad SVP - Corp. Dev. & Strategy	Officer	11 116 Value: $857.6K
Feb 26, 2026 Buy	Common Stock A-Award	Gutwerg Ori SVP, Generics	Officer	12 969 Value: $1.00M
Feb 26, 2026 Buy	Common Stock A-Award	Lalwani Nikhil President & CEO	CEO / President	75 592 Value: $5.83M
Feb 26, 2026 Buy	Common Stock A-Award	Mutz Christopher Head Of Rare Disease	Officer	21 306 Value: $1.64M
Feb 26, 2026 Buy	Common Stock A-Award	Rowland Thomas Andrew SVP, Head - Established Brands	Officer	6 021 Value: $464.5K
Feb 26, 2026 Buy	Common Stock A-Award	Shanmugam Muthusamy Head Of R&d, COO-novitium Ops	C-Suite Officer	11 116 Value: $857.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ANI PHARMACEUTICALS

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development a...

Read Full Profile Here